News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Biomarkers in Gastroesophageal cancer 2025 – An updated consensus statement by the SEOM and SEAP
Maria Alsina Maqueda/navarrabiomed.es
Mar 24, 2025, 12:56

Biomarkers in Gastroesophageal cancer 2025 – An updated consensus statement by the SEOM and SEAP

Nieves Martinez Lago, Medical Oncologist at University Hospital Complex of Ferrol, shared an article Maria Alsina Maqueda and colleagues authored on X:

“Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP).

4 key biomarkers: HER2, dMMR/MSI, PD-L1 and Claudin18.2 by inmunohistochemistry.”

Gastroesophageal cancer

Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP)

Authors: Maria Alsina Maqueda et al.

Gastroesophageal cancer

Ana Fernández Montes Ana Teijo Quintáns cancer Carlos Gómez Martín Carolina Martínez-Ciarpaglini Fernando Rivera Herrero Mar Iglesias Coma Maria Alsina Maqueda Maria Jesús Fernández Aceñero Miriam Cuatrecasas OncoDaily Oncology Paula Jimenez-Fonseca
Special Coverage
Blog
Jun 3, 2025, 11:20
Stephen V Liu: Randomized Phase 3 Trial of Time of Day of Immunotherapy Infusion
Opinion
Jun 3, 2025, 11:15
Armando Orlandi: Day 4 at ASCO 2025 - Key Breast Cancer Clinical Advances 
Blog
Jun 3, 2025, 11:14
Jeff Ryckman Promoted to Associate Professor
Blog
Jun 3, 2025, 11:09
Rafeh Naqash: The Real Star Behind the Scenes who make ASCO a Success Every Year Every Time
Blog
Jun 3, 2025, 10:56
Giannis Mountzios: ASCO25 is About Science, Research, Care but Also Your Second Family - Colleagues and Friends
Blog
Jun 3, 2025, 10:50
Paolo Tarantino: We need Biomarkers to Tailor Treatment with T-DXd
Opinion
Jun 3, 2025, 10:41
TRIgnite-1 study at ASCO 2025 showed High Response Rates and Favorable Safety Profile for the Treatment of Relapsed/Refractory Multiple Myeloma with First-in-Class BCMA × CD38 × CD3 Trispecific Antibody 
Blog
Jun 3, 2025, 10:35
Mario Balsa Shares ASCENT-04 Trial Results in First-Line mTNBC at ASCO25
Blog
Jun 3, 2025, 10:33
Vivek Subbiah: Waiting for ASCO 2025 Hematology Discussions with Naveen Pemmaraju
Blog
Jun 3, 2025, 10:27
Supriya Peshin Reflects on a Memorable Moment with Oncology Colleagues
Blog
Jun 3, 2025, 09:54
Robin Zon: ASCO 2025 President’s Address - “Driving Knowledge to Action: Building a Better Future”
Science
Jun 3, 2025, 09:52
Breaking research on GLP-1s and cancer from ASCO 2025